Login / Signup
Rationale for co-targeting CDK4/6 and FGFR pathways in urothelial carcinoma.
Kyrillus S Shohdy
Panagiotis J Vlachostergios
Raafat R Abdel-Malek
Bishoy M Faltas
Published in:
Expert opinion on therapeutic targets (2018)
Keyphrases
</>
cell cycle
cancer therapy
clinical trial
cell proliferation